Related Experiment Videos
Interferon-alpha treatment of Behçet's disease
J D O'Duffy1, K Calamia, S Cohen
1Mayo Clinic, Rochester, Minnesota 55905, USA.
The Journal of Rheumatology
|October 21, 1998
Summary
Interferon-alpha (IFN-alpha) shows promise in treating Behçet
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Background:
- Behçet's disease (BD) is a chronic inflammatory disorder with multisystemic manifestations.
- Current treatments for BD can have significant side effects and variable efficacy.
Purpose of the Study:
- To evaluate the efficacy and safety of interferon-alpha (IFN-alpha) in patients with active Behçet's disease.
Main Methods:
- An open-label, 6-month trial involving 10 patients with active BD.
- Self-administered subcutaneous IFN-alpha (3 million units daily), with dose adjustments based on response.
- Exclusion of patients with ocular or neurological inflammation at baseline.
Main Results:
- Seven patients completed the trial; three discontinued due to side effects or lack of efficacy.
- Significant reductions observed in oral/genital ulcers, skin lesions, and joint symptoms.
- Decreases in pain scores, global disease assessment, and prednisone dosage were noted.
Conclusions:
- Interferon-alpha (IFN-alpha) appears to be an effective therapy for several manifestations of Behçet's disease.
- While generally well-tolerated, significant side effects including neurological and psychiatric events were reported.